Treatment Of Canine Pyoderma Research Articles

Residual antibacterial activity of canine hair treated with five mousse products against Staphylococcus pseudintermedius invitro.

Topical therapy alone can be effective in the treatment of canine pyoderma. Topical products are commercially available as shampoos, sprays, wipes and mousses. To date, no studies have evaluated the efficacy of commercially available mousse products in the treatment of canine pyoderma. To determine the residual antibacterial activity of canine hairs treated with mousse products containing different active ingredients. Fifteen client-owned dogs with no history of dermatological disease. Dogs were treated once with five mousse products [(i) 2% chlorhexidine and 1% ketoconazole, (ii) 2% chlorhexidine and 2% miconazole, (iii) 3% chlorhexidine and 0.5% climbazole, (iv) 2% salicylic acid 10% ethyl lactate and (v) phytosphingosine HCl 0.05%; control]. Hair samples were collected from each treatment area before application, one hour after application and on days 2, 4, 7, 10 and 14 post-treatment. Collected hairs were weighed and plated on Mueller-Hinton agar plates streaked with a Staphylococcus pseudintermedius isolate showing no antimicrobial resistance. Plates were incubated for 24h and bacterial growth inhibition zones around the hairs were measured. Mousses 1, 2 and 3 created significant inhibition zones up to Day 10 when compared to pre-treatment samples. On Day 14, only mousse 3 produced a significant zone of inhibition when compared to the pre-treatment sample. Mousses 4 and 5 showed no statistical difference between any of the samples. These results suggest that three of the mousse products had residual activity in inhibiting S.pseudintermedius growth invitro for at least 10days.

Descriptive epidemiological study of the use of antimicrobial drugs by companion animal veterinarians in New Zealand

AIM: To describe the patterns of use of antimicrobial drugs by veterinary surgeons treating commonly presented bacterial infections in companion animals in New Zealand. METHODS: A postal survey of 800 randomly selected companion animal veterinarians practicing in New Zealand was conducted between August and December 2008. Data were collected regarding the antimicrobials prescribed for recent cases of skin, ear and urinary tract infections; the use of culture and susceptibility testing; and veterinarian characteristics such as proportion of time spent treating companion animals and recent attendance at continuing professional development (CPD) events. Potential associations within the data were explored using extended mosaic plots and multivariable regression models. RESULTS:Completed surveys from 393 respondents were available for analysis, providing data on systemic antimicrobial drug use for 1,799 cases of presumptive bacterial infections. The most frequently prescribed drugs were amoxicillin-clavulanic acid (864 cases, 48%), cephalexin (558, 31%), and fluoroquinolones (198, 11%). Of 359 cases of canine superficial pyoderma, 157 (44%) were treated with amoxicillin-clavulanic acid and 155 (43%) were treated with cephalexin with median reported treatment durations of 7 and 10 days, for these two drugs respectively. Culture and susceptibility tests had been used in 376 of 1,984 (19%) of all reported cases and 160 (43%) of these were suspected urinary tract infections. Practitioners that spent 100% of their time treating companion animals and who had attended a CPD course related to companion animals within the 12 months prior to completing the survey were more likely to submit a sample for culture and susceptibility testing and to prescribe longer courses of antimicrobials for the treatment of canine pyoderma than practitioners who spent less than 100% of their time treating companion animals and had not attended a CPD course in the last 12 months. CONCLUSIONS: Broad-spectrum drugs considered by the World Health Organisation to be critically important for human health, such as fluoroquinolones and amoxicillin-clavulanic acid, are amongst the most frequently prescribed antimicrobials in companion animal medicine, and these drugs are often prescribed without submitting a sample for culture and susceptibility testing. CLINICAL RELEVANCE: Many cases of superficial pyoderma were treated for less than the recommended duration of 21 days, which may contribute to a higher rate of recurrent pyoderma and the development of drug resistance within the causal bacteria. Veterinarians should be aware that the use of fluoroquinolones, in particular, should be based upon the results of a culture and susceptibility test.

Clinical efficacy and safety of cefovecin in the treatment of canine pyoderma and wound infections

To determine the efficacy and safety of cefovecin in the treatment of bacterial skin infections in dogs. Dogs with superficial or deep pyoderma or wounds/abscesses were enrolled in three separate studies. Dogs (354) were randomised to treatment and received either cefovecin administered by subcutaneous injection at 14 day intervals, as clinically necessary, or amoxicillin/clavulanic acid as oral tablets twice daily for 14 days. Courses of treatment were repeated at 14 day intervals up to a total of four courses. Clinicians responsible for assessing lesions were masked to treatment allocation. Only animals where the presence of a pretreatment bacterial pathogen was confirmed were included in the analysis of efficacy. Cases were evaluated for clinical efficacy at 28 days after initiation of the final course of treatment. Clinical efficacy was assessed by scoring the clinical signs typical of skin infections. Cefovecin demonstrated statistical non-inferiority compared with amoxicillin/clavulanic acid for all three clinical diagnoses; for cefovecin, up to 96.9 per cent efficacy was observed versus 92.5 per cent for amoxicillin/clavulanic acid. Cefovecin was shown to be as effective as amoxicillin/clavulanic acid administered orally in the treatment of bacterial skin infections in dogs. Cefovecin offers the additional benefit of eliminating owner non-compliance.

Treatment of canine pyoderma with co-amoxyclav: a comparison of two dose rates

The efficacy of oral co-amoxyclav, administered twice daily for up to 12 weeks either at the manufacturer's dose rate of 12.5 mg/kg or at 25.0 mg/kg, in curing the lesions...

A Blinded Comparison of the Efficacy of Daily and Twice Daily Trimethoprim‐Sulfadiazine and Daily Sulfadimethoxine‐Ormetoprim Therapy in the Treatment of Canine Pyoderma

Abstract— In a blinded trial to determine the efficacy of potentiated sulfa drugs in the treatment of canine pyoderma, 50 dogs with superficial pyoderma were randomly assigned to receive either once or twice daily trimethoprim‐sulfadiazine (30mg.kg‐1) or once daily sulfadimethoxine‐ormetoprim (55mg.kg‐1 on the first day, then 27.5 mg.kg‐1 thereafter). Dogs were evaluated prior to antibiotic therapy. Clinical efficacy of the antibiotic was assessed after 3 weeks of antibiotic therapy and, if needed, after 6 weeks of antibiotic therapy. Forty‐five dogs completed the study; 43 dogs were used in the statistical analysis. The percentage of dogs that were cured of their pyoderma with once daily trimethoprim‐sulfadiazine was 38.5% by 3 weeks and 75.9% by 6 weeks. With twice daily trimethoprim‐sulfadiazine, 57.1 and 78.6% of dogs were cured by 3 and 6 weeks, respectively. With once daily sulfadimethoxine‐ormetoprim, 75.0 and 100% of dogs were cured by 3 and 6 weeks, respectively. This difference was not statistically significant, possibly due to the low sample size. Few adverse effects were noted.Résumé— Dans une étude en double aveugle pour apprécier l'efficacité des sulfamides potentialisés dans le traitement des pyodermites canines, cinquante chiens présentant une pyodermite superficielle ont reçu, au hasard, soit deux fois ou une fois par jour du triméthoprime‐sulfadiazine (30 mg.kg‐1) ou une fois par jour du sulfadiméthoxine‐ormétoprime (55mg.kg‐1 le premier jour, puis 27.5 mg.kg‐1). Les chiens ont étéévalués avant le traitement. L'efficacité clinique de l'antibiotique a été appréciée après 3 semaines de traitement et, si besion est, après 6 semaines. Le pourcentage de chiens guéris avec une prise quotidienne de triméthoprime‐sulfadiazine était de 33.5%à 3 semaines et 75.9%à 6 semaines. Avec des prises biquotidiennes de triméthoprime‐sulfadiazine 57.1% et 78.6% des chiens étaint guéris à 3 et 6 semaines. Avec une prise quotidienne de sulfadiméthoxine‐ormétoprime, 75.0% et 100.0% des chiens étaient guéris à 3 et 6 semaines. Cette différence n'était pais statistiquement significative, probablement à cause de la taille trop faible de l'échantilon. Très peu d'effects secondaires ont été notés.Zusammenfassung— Für eine Blindstudie zur Bestimmung der Wirksamkeit von potenzierten Sulfonamidpräparaten bei der Behandlung kaniner Pyrodermie wurden 50 Hunde mit oberflächlicher Pyodermie zufällig ausgewählt, um entweder einmal oder zweimal täglich Trimethoprim‐Sulfadiazin (30mg/kg) oder einmal täglich Sulfadimethoxin‐Ormetoprim zu erhalten (55 mg/kg am ersten Tag, danach 27,5 mg/kg). Die Hunde wurden vor der antibotischen Therapie untersucht. Die klinische Wirksamkeit der Antibiose wurde nach 3 Wochen antibiotischer Therapie und, wenn nötig, nach 6 Wochen antibiotischer Therapie ausgewertet. 45 Hunde durchliefen die Studie vollständig; 43 Hunde fanden in die statistische Analyse Eingang. Der Prozentsatz der Hunde, deren Pyrodermie durch einmal tägliches Trimethoprim‐Sulfadiazin geheilt wurde, lag bei 38,5% nach 3 Wochen und bei 75,9% nach 6 Wochen. Bei zweimaliger Trimethoprim‐Sulfadiazin‐Verabreichung wurden 57,1% und 78,6% der Hunde nach 3 bzw. 6 Wochen geheilt. Mit einer einmal täglichen Verabreichung von. Sulfadimethoxin‐Ormetoprim wurden 75,0% und 100% der Hunde nach 3 bzw. 6 Wochen geheilt. Dieser Unterschied war statistisch nicht signifikant, möglicherweise aufgrund der geringen Fallzahlen. Es wurden nur wenige Nebenwirkungen festgestellt.Resumen A cincuenta perros que presentaban pioderma superficial se les evaluó para la eficacia de antibioticos potenciados de tipo sulfamídico en el tratamiento del pioderma canino, por medio de la administración de una a dos veces diarias de trimetoprim‐sulfadiazina (30 mg/kg), o sulfadimetoxinaormetoprim una vez al día (55 mg/kg en al primer día, y 27.5 mg/kg después de la primera dosis). Los animales se examinaron antes del tratamiento con antibióticos. La eficacia clínica del tratamiento se evaluó a las tres o seis semanas en los casos necesarios. Cuarenta y cinco de los perros completaron el estudio; 43 se utilizaron en analisis estadísticos. El porcentaje de perros curados con el tratamiento diario a base de trimetoprim‐sulfadiazina fué del 38.5% a las 3 semanas, y 75.9% a las 6 semanas. De los animales tratados dos veces al día con trimetoprim‐sulfadiazina, el porcentaje de cura fue del 57.1% y 78.6%, a las 3 y 6 semanas respectivamente. Con el tratamiento a base de sulfadimetoxina‐ormetoprim una vez al día, 75.0% y 100% de los perros fueron curados a las tres y seis semanas. La diferencia no se encontró estadísticamente significativa, posiblemente debido al reducido número de perros evaluados. Se observaron posas reacciones adversas a la medicación.